Julian Upton is the European Editor of Pharmaceutical Executive and Editor of Pharm Exec Global Digest. He can be reached at email@example.com.
Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box?"
Value-based pricing in the United Kingdom is getting closer, but it remains out of focus.
After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase. Julian Upton reports.
Takeda's new $96 million plant in Russia is further proof of its expansive efforts to catch up in the BRIC countries. That is, the BRIC countries minus India. Chief Commercial Office Dr Frank Morich explains.
As a drug company promoting a drug free Olympiad, GSK wins our gold hands down for finally putting the industry's best face forward on the last frontier of advertising—the TV sets of Europe.
Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value?
A recent global CEO report reveals that 51% of pharma CEOs think it has become more difficult to hire workers within the sector, outweighing the same problem in all other industries surveyed.
In establishing the value of new medicines, old-way theory is yielding to real-world practice — but there are risks in being 'of the moment'.
Pharma has become unusually quick to strike embrace the iPad. But the industry's inherent conservatism means it has some way to go to fully milk the device's potential.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial